- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05286086
Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative (PREHAREC)
Randomized Controlled Trial Comparing the Effect of a Multimodal Prehabilitation Program During Neoadjuvant Treatment Versus a Multimodal Prehabilitation After Neoadjuvant Treatment for Patients Undergoing Resection of Rectal Cancer.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
According to the annual report of the Spanish Medical Oncology Association (SEOM), in Spain and without differentiating by sex, colorectal cancer will be the cancer with the highest incidence by 2021; with 43.581 new cases estimated for such year, 14.209 of these will be of rectal cancer. In rectal cancer, surgery remains the cornerstone; however, it is already known that local recurrences are frequent. That is why one of the main milestones rectal cancer treatment, is the multimodal therapy approach. It consists of implementing a neoadjuvant chemoradiotherapy treatment (NCRT) prior to surgical intervention. With this, local control of the disease is achieved, metastases are reduced have resulted in a five-year survival. Subsequently, depending on the definitive pathological results, patients should also complete treatment with postoperative chemotherapy. It is known that patients undergoing neoadjuvant treatment experience a wide variety of side effects, which can cause loss of muscle and cardiovascular function, loss of their functional capacity and increased fatigue. This worsens the quality of life of the patient and can sometimes cause the interruption of neoadjuvant treatment and have repercussions on the prognosis. Not only do these side effects affect the course of neoadjuvant treatment, but also declines the physiological reserve, making the patient arrive in sub-optimal conditions for surgery. This has an impact on postoperative morbidity and mortality, and secondarily, in the increase of hospital stay.
The concept of functional capacity appears ¨as the nutritional, physical and emotional state that a person has to face a stressful situation, such as surgical treatment. It is believed that if functional capacity is enhanced, postoperative morbidity can be reduced and the patient's recovery can also be improved. That is why trimodal programs are created, specifically selected for their potential cumulative or synergistic effects on health outcomes to prepare patients to face surgery at all three levels. These programs are known as prehabilitation.
Currently there are studies that show that prehabilitation improves the results of patients who must undergo different major surgical procedures, among them in colorectal surgery. Our group has recently presented a study that shows that trimodal prehabilitation contributes to reducing postoperative morbidity and overall hospital stay in patients operated on for colorectal neoplasia. There are also systematic reviews that conclude that prehabilitated patients who must undergo major surgery (speaking of 435 patients and 9 studies) present a decrease in the incidence of major postoperative complications. On the other hand, there are studies that show that prehabilitation in patients who must receive neoadjuvant therapy reduces the decrease of functional capacity that treatment produces on patients. As also shown by the Rex Trial, a randomized study on 48 patients. In an attempt to unite the two lines start the study, it will be a novel one , with only two previously published studies in this area. The intention is demonstrate that when prehabilitation is started before commencing neoadjuvant therapy in patients who are diagnosed with rectal cancer and who are subject to neoadjuvant therapy, will reduce the effect on functional capacity, and that patients will present less postoperative morbidity and better postoperative recovery.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Laura Mora
- Telefonnummer: 21490 34 937211010
- E-mail: mora.lopez.laura@gmail.com
Undersøgelse Kontakt Backup
- Navn: Laura Mora, Dr
- Telefonnummer: 21490 34 937211010
- E-mail: mora.lopez.laura@gmail.com
Studiesteder
-
-
Barcelona
-
Sabadell, Barcelona, Spanien, 08208
- Laura Mora López
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patient with rectal tumour and selected to initiate NRCT
- Patient must know the study and sign informed consent.
- Patient must accept the conditions necessaries to carry out the prehabilitation.
Exclusion Criteria:
- Refusal of the patient to sign the informed consent.
- Baseline pathology that makes it impossible to carry out prehabilitation.
- Progression of the disease during the study period.
- Emergency surgery.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Sham-komparator: PREHAB-PREOP
PREHABILITATION BEFORE SURGERY
|
Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery
|
Eksperimentel: PREHAB-NEOADJ
PREHABILITATION DURING NEOADJUVANCY AND BEFORE SURGERY
|
Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Comprehension Complication Index (CCI)
Tidsramme: through study completion, an average of 1 yea
|
Morbidity after surgery of rectal cancer: CCI - value 0-100
|
through study completion, an average of 1 yea
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
6 minutes walking test (6MWT)
Tidsramme: through study completion, an average of 1 yea
|
Walking test that helps calculation of the number of daily steps to be carried out (5.000 to 10.000) daily steps
|
through study completion, an average of 1 yea
|
Hospital Anxiety and Depression Scale (HADS) test : anxious and depresion scale
Tidsramme: through study completion, an average of 1 yea
|
Calculation of level of anxiety or depression in mild, moderate or severe.
Allows referral of the patient to the psychology service
|
through study completion, an average of 1 yea
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Laura Mora, Dr, Parc Tauli University Hospital
Publikationer og nyttige links
Generelle publikationer
- Berho M, Narang R, Van Koughnett JA, Wexner SD. Modern multidisciplinary perioperative management of rectal cancer. JAMA Surg. 2015 Mar 1;150(3):260-6. doi: 10.1001/jamasurg.2014.2887.
- Herman JM, Narang AK, Griffith KA, Zalupski MM, Reese JB, Gearhart SL, Azad NS, Chan J, Olsen L, Efron JE, Lawrence TS, Ben-Josef E. The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e15-9. doi: 10.1016/j.ijrobp.2012.09.006. Epub 2012 Oct 9.
- Pramateftakis MG, Kanellos D, Tekkis PP, Touroutoglou N, Kanellos I. Rectal cancer: multimodal treatment approach. Int J Surg Oncol. 2012;2012:279341. doi: 10.1155/2012/279341. Epub 2012 Sep 12. No abstract available.
- Gillis C, Fenton TR, Sajobi TT, Minnella EM, Awasthi R, Loiselle SE, Liberman AS, Stein B, Charlebois P, Carli F. Trimodal prehabilitation for colorectal surgery attenuates post-surgical losses in lean body mass: A pooled analysis of randomized controlled trials. Clin Nutr. 2019 Jun;38(3):1053-1060. doi: 10.1016/j.clnu.2018.06.982. Epub 2018 Jul 9.
- Wright S, Wiechula R, McLiesh P. The effectiveness of prehabilitation for adults having elective surgery: a systematic review protocol. JBI Database System Rev Implement Rep. 2016 Feb;14(2):78-92. doi: 10.11124/jbisrir-2016-2460. No abstract available.
- Santa Mina D, van Rooijen SJ, Minnella EM, Alibhai SMH, Brahmbhatt P, Dalton SO, Gillis C, Grocott MPW, Howell D, Randall IM, Sabiston CM, Silver JK, Slooter G, West M, Jack S, Carli F. Multiphasic Prehabilitation Across the Cancer Continuum: A Narrative Review and Conceptual Framework. Front Oncol. 2021 Jan 11;10:598425. doi: 10.3389/fonc.2020.598425. eCollection 2020.
Datoer for undersøgelser
Studer store datoer
Studiestart (Forventet)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PREHAREC
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Endetarmskræft, Adenocarcinom
-
Sunnybrook Health Sciences CentreUniversity of Toronto; Sunnybrook Research InstituteAfsluttetRectal Neoplasma Carcinoma in Situ AdenocarcinomaCanada
-
Sir Run Run Shaw HospitalAktiv, ikke rekrutterendeMSS Locally Advanced Rectal AdenocarcinomaKina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeKlinisk trin III Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Klinisk trin IV Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Uoperabelt Gastroøsofageal Junction Adenocarcinoma | Lokalt avanceret Gastroøsofageal Junction Adenocarcinoma | Postneoadjuverende terapi Stage III Gastroøsofageal... og andre forholdForenede Stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeEsophageal Adenocarcinom | Esophageal pladecellekarcinom | Klinisk trin III Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Klinisk fase II Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Klinisk fase IVA Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Patologisk trin IIIA Gastroøsofageal... og andre forholdForenede Stater
-
M.D. Anderson Cancer CenterRekrutteringKlinisk fase III gastrisk cancer AJCC v8 | Klinisk trin III Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Klinisk fase IV gastrisk cancer AJCC v8 | Klinisk trin IV Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Metastatisk gastrisk adenocarcinom | Metastatisk Gastroøsofageal Junction Adenocarcinoma og andre forholdForenede Stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AfsluttetGastroøsofageal Junction Adenocarcinom | Stadie IB Esophageal Adenocarcinoma AJCC v7 | Stadie II Esophageal Adenocarcinoma AJCC v7 | Stadie IIA Esophageal Adenocarcinoma AJCC v7 | Stadie IIB Esophageal Adenocarcinoma AJCC v7 | Stadie IIIA Esophageal Adenocarcinoma AJCC v7 | Stadie IIIB Esophageal...Forenede Stater
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RekrutteringKlinisk fase III gastrisk cancer AJCC v8 | Klinisk trin III Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Klinisk fase IV gastrisk cancer AJCC v8 | Klinisk trin IV Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Metastatisk gastrisk adenocarcinom | Metastatisk Gastroøsofageal Junction Adenocarcinoma og andre forholdForenede Stater
-
NRG OncologyNational Cancer Institute (NCI)RekrutteringKlinisk trin III Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Uoperabelt Gastroøsofageal Junction Adenocarcinoma | Postneoadjuverende terapi Stage III Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Postneoadjuverende terapi trin IIIA Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Postneoadjuverende... og andre forholdForenede Stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeGastrisk Adenocarcinom | Klinisk trin III Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Klinisk fase 0 Mavekræft AJCC v8 | Klinisk fase I gastrisk cancer AJCC v8 | Klinisk fase IIB gastrisk cancer AJCC v8 | Klinisk fase IVA gastrisk cancer AJCC v8 | Patologisk fase 0 Mavekræft AJCC v8 | Patologisk... og andre forholdForenede Stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)AfsluttetKlinisk fase IV gastrisk cancer AJCC v8 | Klinisk trin IV Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Metastatisk gastrisk adenocarcinom | Metastatisk Gastroøsofageal Junction Adenocarcinoma | Postneoadjuverende terapi Stage IV Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Postneoadjuverende... og andre forholdForenede Stater